Arkyn raises EUR 3.8 million in seed capital investment round led by Trifork Labs
Press release
Copenhagen, April 26, 2022 – Arkyn, the SaaS mobile app company on a mission to make it easy to use SAP, has raised EUR 3.8 million in an investment round from Trifork Labs, the founders and management, and other private investors.
Founded in 2020, Arkyn delivers pre-developed iOS apps and a platform that fits on top of SAP’s processes like plant maintenance, customer service and field service. The company helps enterprises increase productivity, optimize work processes, and increase the quality of data reported by employees. Enabling time savings, cost optimizations and new insights.
“We are pleased by the trust and confidence shown by our investors. The funds allow us to continue
to develop that critical link between the back-office super users of SAP and field technicians who need user friendly mobile apps to gather information and feedback data from anywhere,whether it is 300 feet below ground in a subway or high up in a wind turbine,” says Nicolai Elmqvist, CEO & Co-founder of Arkyn.
The funds raised will be used for further product development, sales and marketing activities across Europe targeting enterprises within manufacturing and railway as well as re-selling partners like Trifork or ATEA.
“The Arkyn team has been working with design thinking and mobile interfaces for SAP for many years, changing complex processes into safe, efficient, and intelligent user experiences. Arkyn has played a vital role for Trifork’s Smart Enterprise show case solution to Banedanmark, and we are pleased to continue to support the company and to welcome the new co-investors,” says Jørn Larsen, CEO and founder of Trifork.
Arkyn’s app suite currently consists of four apps used by field technicians within the manufacturing and railway industry. FastAssets deliver valuable insights about the maintenance history in a production line or on a railway, FastFieldwork helps technicians understand and report their work on location through features like speech to text, FastTime enables simple time registration and FastForms is a tool to replace paper forms or excel sheets that are still widely used across industries due to lack of alternatives. All apps are connected to Arkyn’s platform that enables real-time synchronization of data with the customers’ local SAP installation.
For further information:
Arkyn: CEO Nicolai Elmqvist, +45 2944 4108, ne@arkyn.io
Trifork: CMO Peter Rørsgaard, +45 2042 2494, pro@trifork.com
About Arkyn (www.arkyn.io)
Arkyn, headquartered in Copenhagen, Denmark, is a SaaS startup focusing on creating user-friendly apps for enterprises using SAP and a middleware that makes integration with the customers’ on-premise SAP installation easy. The app suite currently contains 4 different apps that are designed to improve efficiency, data quality and to make life easier for blue collar workers like field technicians, maintenance planners who are not SAP super-users. Arkyn is currently focusing on the manufacturing and railway industry. Including pharmaceuticals & life science, food & beverage, automotive, utilities, chemicals, oil & gas, renewable energy and more. Founded in 2020 by Trifork Labs and former Invokers founders (today Trifork Smart Enterprise), Arkyn today has 15 employees and among the customers are the Danish national railway company Banedanmark and global maritime safety company Viking. Read more on: www.arkyn.io
About Trifork (trifork.com)
Trifork is a global NextGen IT company that develops innovative software solutions in collaboration with its customers. The company has more than 950 employees, across 58 business units, with offices in 12 countries in Europe and the USA, and works in six business areas: Digital Health, FinTech, Smart Building, Cloud Operations, Cyber Protection and Smart Enterprise. Trifork’s research and development takes place in Trifork Labs, where Trifork continuously co-invests and develops technology start-up companies. Trifork is behind the brand, GOTO, which runs a global tech community with over 275,000 subscribers and more than 30 million views on YouTube.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
IBFD launches the 2021 Yearbook on Taxpayers’ Rights19.5.2022 10:00:00 CEST | Press release
Today, IBFD launches the 2021 Yearbook on the Protection of Taxpayers’ Rights (OPTR). The book is a compilation of up-to-date information on the effective protection of taxpayers’ rights. AMSTERDAM, May 19, 2022 (GLOBE NEWSWIRE) -- Prof. Dr Pasquale Pistone and Prof. Dr Philip Baker, Directors of IBFD’s OPTR, will present the Yearbook at the 7th International Conference on Taxpayer Rights, hosted by the Center for Taxpayer Rights, explaining some of the main events and trends that arose last year in the protection of taxpayers’ rights around the world. Click here to watch the video. The OPTR reports on the protection of taxpayers’ fundamental rights around the world. The precise and technical information of the OPTR contains reference to taxpayer bills, conventions and statutes, including their judicial and administrative interpretation, which explore how states apply this protection in practice. The OPTR serves as a unique legal basis for developing further research on the legal remed
Centrient Pharmaceuticals announces its achievement of a significant milestone in the clean production of antibiotics19.5.2022 10:00:00 CEST | Press release
Being the first company to publicly announce 100% PNEC compliance for its entire oral antibiotics product range Rijswijk, The Netherlands, May 19, 2022 (GLOBE NEWSWIRE) -- Summary Centrient Pharmaceuticals reached a significant milestone in the clean production of its antibiotics, with the lowest environmental impact and minimizing the potential contribution to antimicrobial resistanceThe company is the first to publicly announce that Its entire supply chain of oral antibiotics – including its own and supplier manufacturing sites - is fully compliant with the stringent Predicted No Effect Concentration (PNEC) discharge targets set by the AMR Industry AllianceThis achievement demonstrates Centrient Pharmaceuticals’ commitment and leadership in the responsible production of antibiotics. Centrient Pharmaceuticals announces 100% compliance with the stringent Predicted No Effect Concentration (PNEC) discharge targets set by the AMR Industry Alliance for clean manufacturing of its full oral
Share Buyback Transaction Details May 12 – May 18, 202219.5.2022 10:00:00 CEST | Press release
Share Buyback Transaction Details May 12 – May 18, 2022 May 19, 2022 - Wolters Kluwer today reports that it has repurchased 118,000 of its own ordinary shares in the period from May 12, 2022, up to and including May 18, 2022, for €11.0 million and at an average share price of €92.92. These repurchases are part of the share buyback program announced on February 23, 2022, under which we intend to repurchase shares for up to €600 million during 2022. The cumulative amounts repurchased to date under this program are as follows: Share Buyback 2022 PeriodCumulative shares repurchased in period Total consideration (€ million)Average share price (€) 2022 to date 2,573,464 238.4 92.64 For the period starting May 5, 2022, up to and including August 1, 2022, we have engaged a third party to execute €140 million of buybacks on our behalf, within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company’s Articles of Association. Repurchased shares are add
Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)19.5.2022 09:01:00 CEST | Press release
Dante Labs is a Global Leader in Genomics and Precision MedicineMainz is Exclusively Focused on Developing Next Generation Diagnostics for the Early Detection of Cancer BERKELEY, Calif. and MAINZ, Germany and NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer and Dante Labs, a global leader in genomics and precision medicine, announced today a partnership for the commercialization of ColoAlert in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz’s flagship product, a highly efficacious and easy to use at-home detection test for colorectal cancer (CRC). Dante Labs is a global leader in genome sequencing with a product development and commercial franchise focused on providing personalized preventive healthcare solutions by leveraging its robust databases and proprietary software platform to offer next-generation diagnostic tools direct to co
Regarding the approval of the key financial performance indicators for AB Klaipėdos nafta for the period of 2022-202419.5.2022 08:22:29 CEST | Press release
AB Klaipėdos nafta (hereinafter – the Company) hereby informs that the Government of the Republic of Lithuania on 18 May 2022 adopted the resolution No. 509 “Regarding the approval of the key financial performance indicators for state-owned enterprises for the period of 2022-2024”, which establishes the following performance indicators for the Company: Indicator202220232024Average annual adjusted EBITDA* Period 2022–2024 ≥ EUR 33.9 millionAnnual financial debt to equity ratio Period 2022–2024 limit 1.7–3.2 times * EBITDA less adjustment (temporary regulatory differences, temporary fluctuations in the fair value of financial derivatives, results from disposal or revaluation of non-current assets, compensations received for previous periods, other non-typical corrections). Mindaugas Kvekšas, Chief Financial Officer, +370 46 391772